A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer and Systemic Inflammation

Giuseppe Giaccone, Rachel E. Sanborn, Saiama N. Waqar, Alex Martinez-Marti, Santiago Ponce, Huiling Zhen, Gerard Kennealey, Susan Erickson-Viitanen, Eric Schaefer

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

This was a 2-part trial of ruxolitinib plus pemetrexed/cisplatin for nonsquamous non–small-cell lung cancer. Part 1 (15 patients) identified ruxolitinib 15 mg twice daily as dose of choice, with an acceptable safety profile. Because the study was terminated early, interpretation of efficacy data from part 2 is limited (double-blind; at termination, 39 and 37 patients were randomized to ruxolitinib and placebo, respectively). Background: Dysregulation of the Janus kinase (JAK)/signal transducers and activators of transcription pathway contributes to abnormal inflammatory responses and poor prognosis in non–small-cell lung cancer (NSCLC). We evaluated the JAK1/JAK2 inhibitor ruxolitinib plus pemetrexed/cisplatin first-line in patients with stage IIIB/IV or recurrent nonsquamous NSCLC with systemic inflammation (modified Glasgow prognostic score [mGPS] 1/2). Patients and Methods: Part 1 was an open-label, safety run-in, in which we assessed ruxolitinib (15 mg twice daily [b.i.d.]) plus pemetrexed (500 mg/m 2 intravenous, day 1) and cisplatin (75 mg/m 2 intravenous, day 1). Ruxolitinib dose selection for part 2 required <3 dose-limiting toxicities (DLTs) for 9 evaluable patients. In part 2 patients were randomized to ruxolitinib or placebo (each plus pemetrexed/cisplatin). The trial terminated early for reasons unrelated to this trial. Results: Fifteen patients enrolled in part 1 (median age, 64 years; 80% male, 80% mGPS 1) received ruxolitinib 15 mg b.i.d. plus pemetrexed/cisplatin. Median treatment duration was 140 days and no DLTs occurred in 11 evaluable patients. No new safety concerns arose when ruxolitinib was combined with pemetrexed/cisplatin. At study termination, 39 patients were randomized to ruxolitinib and 37 to placebo in part 2. Median treatment duration was 43 days. Response rate was 31% (12 of 39) with ruxolitinib and 35% (13 of 37) with placebo (all partial responses). Conclusion: Ruxolitinib 15 mg b.i.d. had an acceptable safety profile in combination with pemetrexed/cisplatin asfirst-line treatment of patients with stage IIIB/IV or recurrent nonsquamous NSCLC and systemic inflammation. Early study termination limited the interpretation of efficacy data in the randomized phase II part of the study.

Original languageEnglish
Pages (from-to)e567-e574
JournalClinical Lung Cancer
Volume19
Issue number5
DOIs
StatePublished - Sep 2018

Keywords

  • JAK1
  • JAK2
  • Janus kinase (JAK)
  • Modified Glasgow prognostic score
  • Signal transducers and activators of transcription (STAT)

Fingerprint Dive into the research topics of 'A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer and Systemic Inflammation'. Together they form a unique fingerprint.

  • Cite this